depression

News

rofessor John Atack and Professor Simon Ward, from Cardiff University’s Medicines Discovery Institute

Welsh biotech Draig emerges with $140m in financing

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

News

Consolidation in psychedelics as atai pairs with Beckley

Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

One of J&J's blockbuster depression hopes has flamed out

Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.

News

Supernus reports less than super data for depression drug

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial.

News

Dr Villy Valcheva, CEO of Dublin, Ireland-based GH Research

GH Research leaps on psychedelic data in depression

After setbacks with psychedelics, phase 2b data with GH Research's GH001 for treatment-resistant depression could lift confidence in the category.

Welsh biotech Draig emerges with $140m in financing

Consolidation in psychedelics as atai pairs with Beckley

Beckley's psychedelic med inches forward in depression

One of J&J's blockbuster depression hopes has flamed out

Supernus reports less than super data for depression drug

GH Research leaps on psychedelic data in depression

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

depression

Editor's Picks